Andrea De Giglio

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study

Antonio Tursi, Giovanni Brandimarte, Alfredo Papa et al. · The American Journal of Gastroenterology · 2010 · 483 citations · Full text

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 400 citations · Full text

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Biagio Ricciuti, Carlo Genova, Andrea De Giglio et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 357 citations · Full text

Medicine, Immunology, Multi-institutional Analysis +8

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash et al. · Journal of Clinical Oncology · 2019 · 192 citations · Full text

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Alessio Cortellini, Melissa Bersanelli, Daniele Santini et al. · European Journal of Cancer · 2020 · 120 citations

Cancer Immunosurveillance, Medicine, Body Mass Index +12